-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Inari Medical Analyst Ratings
Inari Medical Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
09/16/2022 | 27.46% | Canaccord Genuity | $92 → $94 | Maintains | Buy |
09/13/2022 | 17.97% | Truist Securities | → $87 | Initiates Coverage On | → Hold |
07/15/2022 | 26.1% | Morgan Stanley | $108 → $93 | Maintains | Overweight |
06/24/2022 | 35.59% | BTIG | $130 → $100 | Maintains | Buy |
06/21/2022 | 35.59% | Piper Sandler | → $100 | Initiates Coverage On | → Overweight |
03/14/2022 | 30.17% | Canaccord Genuity | $102 → $96 | Maintains | Buy |
02/24/2022 | 46.44% | Morgan Stanley | $119 → $108 | Maintains | Overweight |
02/24/2022 | 28.81% | SVB Leerink | $85 → $95 | Maintains | Outperform |
11/10/2021 | 62.71% | SVB Leerink | $110 → $120 | Maintains | Outperform |
08/11/2021 | 49.15% | SVB Leerink | $126 → $110 | Maintains | Outperform |
05/12/2021 | 78.98% | Canaccord Genuity | $129 → $132 | Maintains | Buy |
05/12/2021 | 74.92% | Morgan Stanley | $126 → $129 | Maintains | Overweight |
03/10/2021 | 69.49% | Wells Fargo | $112 → $125 | Maintains | Overweight |
03/10/2021 | 74.92% | Canaccord Genuity | $94 → $129 | Reiterates | → Buy |
03/10/2021 | 70.85% | Morgan Stanley | $85 → $126 | Maintains | Overweight |
03/10/2021 | 70.85% | SVB Leerink | $116 → $126 | Maintains | Outperform |
12/15/2020 | 7.12% | Wells Fargo | → $79 | Upgrades | Equal-Weight → Overweight |
11/18/2020 | 24.75% | BTIG | → $92 | Initiates Coverage On | → Buy |
11/13/2020 | 15.25% | Morgan Stanley | $76 → $85 | Maintains | Overweight |
11/13/2020 | 22.03% | SVB Leerink | $80 → $90 | Maintains | Outperform |
09/28/2020 | 8.47% | SVB Leerink | → $80 | Initiates Coverage On | → Outperform |
08/12/2020 | -10.51% | Morgan Stanley | $52 → $66 | Maintains | Equal-Weight |
06/22/2020 | -18.64% | Canaccord Genuity | → $60 | Initiates Coverage On | → Buy |
06/19/2020 | -18.64% | Canaccord Genuity | → $60 | Initiates Coverage On | → Buy |
06/16/2020 | -33.56% | Wells Fargo | → $49 | Initiates Coverage On | → Equal-Weight |
06/16/2020 | -29.49% | Morgan Stanley | → $52 | Initiates Coverage On | → Equal-Weight |
Inari Medical Questions & Answers
The latest price target for Inari Medical (NASDAQ: NARI) was reported by Canaccord Genuity on September 16, 2022. The analyst firm set a price target for $94.00 expecting NARI to rise to within 12 months (a possible 27.46% upside). 9 analyst firms have reported ratings in the last year.
The latest analyst rating for Inari Medical (NASDAQ: NARI) was provided by Canaccord Genuity, and Inari Medical maintained their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Inari Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Inari Medical was filed on September 16, 2022 so you should expect the next rating to be made available sometime around September 16, 2023.
While ratings are subjective and will change, the latest Inari Medical (NARI) rating was a maintained with a price target of $92.00 to $94.00. The current price Inari Medical (NARI) is trading at is $73.75, which is out of the analyst's predicted range.
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧